2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1878

A Combination of Celecoxib and Famciclovir Is Efficacious in the Treatment of Fibromyalgia: Results of a Phase IIa Randomized, Double-Blind, Placebo-Controlled Study
Abstract Number: 2580

A Comparison of Baseline Characteristics and Real-Life Effectiveness of Anti-TNF Therapy in Non-Radiographic Axial Spondyloarthritis Versus Ankylosing Spondylitis – a Single Center Cohort Study
Abstract Number: 673

A Comparison of Rheumatoid Arthritis and Systemic Lupus Erythematosus Trial Design: Ways to Improve Positive Trials in Systemic Lupus Erythematosus
Abstract Number: 1374

A Comparison of the Risk for Cardiovascular Event in Patients with Rheumatoid Arthritis Treated with Biologic Disease Modifiers and Patients Treated with Methotrexate Only
Abstract Number: L2

A Comparison of Three Treatment Strategies in Recent Onset DMARD Naïve Juvenile Idiopathic Arthritis: 3-Months Results of the BeSt for Kids-Study
Abstract Number: 912

A Consensus Hybrid Definition Using a Conjoint Analysis Is the Proposed As Response Criteria for Minimal and Moderate Improvement for Adult Polymyositis and Dermatomyositis Clincal Trials
Abstract Number: 299

A Controlled Trial of Intra-Articular Corticosteroids with or without Methotrexate in Oligoarticular Juvenile Idiopathic Arthritis
Abstract Number: 2065

A Cross-Sectional Analysis of Psychological Symptoms, Sleep Quality, and Functional Balance in Fibromyalgia
Abstract Number: 1299

A Cross-Sectional Study of Mental Health Symptoms and Mental Health Care in Pediatric SLE/MCTD Patients and Their Peers
Abstract Number: 145

A Cut-Off Value Analysis By Ultrasound for the Diagnosis of Giant Cell Arteritis (GCA)
Abstract Number: 1349

A Decision Support Tool to Improve Herpes Zoster Vaccination Rates Among Patients Starting Biologic Medications
Abstract Number: 1167

A Description and Comparison of Treatments for Low Back Pain in the United States
Abstract Number: 526

A Descriptive and Comparative Study of the Transcriptome from Salivary Exosomes of Sjögren’s Syndrome Patients Using RNA-Seq
Abstract Number: 909

A Diagnostic Protocol for Giant Cell Arteritis (GCA) Using Ultrasound Assessment
Abstract Number: 729

A Dilated Esophagus Is an Independent Risk Factor for Interstitial Lung Disease in SSc

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].